HANSOH Aktie

 

Nomura said in a research report that, benefiting from the stable growth of Ameile and the continued volume expansion of Flumatinib, it forecast HANSOH PHARMA (03692.HK)'s oncology drug sales to grow 15% YoY in 1H26, driving revenue up 11% YoY to RMB8.248 billion. However, net profit is expected to fall 4.5% YoY to RMB2.992 bill......

CLSA said in a research report that HANSOH PHARMA (03692.HK), as the Hong Kong-listed biopharmaceutical company with the highest proportion of innovative drug revenue, demonstrated balanced growth in the steady advancement of innovative drugs and strong out-licensing in 2025. Driven by continued ramp-up in innovative drug sales,......

HANSOH PHARMA (03692.HK) announced that Avere (an investee company of the Company) and NextCure (NXTC.US) entered into a merger agreement, pursuant to which Avere will be merged into NextCure. In connection therewith, the Group (i) has granted an exclusive license to Avere in respect of HS-20118 (AVR-001), a cyclic peptide inter......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) licensor Hansoh Pharmaceutical Group announced that ARTEMIS-008, its phase III trial evaluating risvutatug rezetecan or Ris-Rez in patient......

An experimental drug GSK Plc is developing with Hansoh Pharmaceutical Group helped patients with small-cell lung cancer live for longer in a late-stage Chinese trial....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CMBI issued a research report noting that the MSCI China Healthcare Index has cumulatively declined by 11.4% since the beginning of 2026, outperforming the MSCI China Index by 0.2 ppts. The broker believes the recent pullback in the pharmaceutical sector was mainly affected by liquidity factors, policy factors and geopolitics. H......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HANSOH PHARMA (03692.HK) announced that the New Drug Application (NDA) for its innovative drug Olipudase Injection was accepted yesterday (3rd) by the National Medical Products Administration (NMPA) in China, for long-term weight management in adults with obesity or overweight.Olipudase is a once-weekly glucagon-like peptide-1 (......

Hang Seng Indexes Company announced today (22nd) the results of its quarterly review as of end-March. The Hang Seng China Enterprises Index (HSCEI) will add HANSOH PHARMA (03692.HK) and AKESO (09926.HK), and remove SUNNY OPTICAL (02382.HK) and HAIER SMARTHOME (06690.HK). The number of constituents will remain unchanged at 50. Al......

HANSOH PHARMA (03692.HK) announced that on May 21 (yesterday), its self-developed fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), HS-10504 tablets, was approved by the National Medical Products Administration for inclusion as a Breakthrough Therapy. The proposed indication is for the trea......

HANSOH PHARMA (03692.HK) announced that its self-developed Class 1 innovative drug HS-10541 tablet has received a Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) of China. The company plans to conduct clinical trials for the treatment of KRAS G12C-mutated advanced solid tumors.(ha/u)~......

HANSOH PHARMA (03692.HK) announced that on May 9, the groups self-developed B7-H3-targeted antibody-drug conjugate (ADC), HS-20093 for injection, was approved by the National Medical Products Administration (NMPA) of China for inclusion as a Breakthrough Therapy Drug. The proposed indication is for unresectable locally advanced......

HANSOH PHARMA (03692.HK) announced that its wholly-owned subsidiary (the original licensee), which had obtained an exclusive license from KiOmed to develop and commercialize KiOmedine One for the treatment of osteoarthritis in Mainland China, Hong Kong, Macau and Taiwan, has entered into a novation agreement to transfer all righ......

HANSOH PHARMA (03692.HK) announced that its self-developed B7-H3-targeted antibody-drug conjugate (ADC), HS-20093 for injection, has been approved by the National Medical Products Administration of China for inclusion as a Breakthrough Therapy Drug. The proposed indication is for advanced castration-resistant prostate cancer pre......

HANSOH PHARMA (03692.HK) announced that its self-developed Class 1 innovative drug, HS-10522 tablets, has received two Drug Clinical Trial Approval Notices issued by the National Medical Products Administration of China. The approvals allow the company to conduct clinical trials for the treatment of uncontrolled hypertension and......

Hansoh Biotech-B (03378.HK) announced that at the 2026 American Association for Cancer Research (AACR) Annual Meeting held in San Diego, the United States from April 17 to 22, the company presented four core preclinical research results in poster sessions. These included: a preclinical pharmacokinetic and pharmacodynamic model s......

Biotech Veterans Jeff Jonas and Al Robichaud to Lead Company with Investment from Cure Ventures, The Column Group, and AN VenturesFRAMINGHAM, Mass.--(BUSINESS WIRE)--#ANVentures--Tortugas Neuroscience (“Tortugas”), a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, today announces $106 million in Seed and Series A financings. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates. Founding investor Cure Ventures, a life sciences venture capital firm focusing on de novo company formation around groundbreaking technologies, led the Seed round, and will co-lead the Series A round along with The Column Group and AN Venture Partners. In-licensed from Eisai Co., Ltd. (Tokyo, Japan) and Jiangsu Hansoh Pharmaceutical Group Ltd. (Greater China), the clinical stage pipeline includes potential treatments for schizophrenia, tinnitu...